Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Nat Chem Biol ; 15(7): 666-668, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31209353

RESUMO

The complement pathway is an important part of the immune system, and uncontrolled activation is implicated in many diseases. The human complement component 5 protein (C5) is a validated drug target within the complement pathway, as an anti-C5 antibody (Soliris) is an approved therapy for paroxysmal nocturnal hemoglobinuria. Here, we report the identification, optimization and mechanism of action for the first small-molecule inhibitor of C5 complement protein.


Assuntos
Complemento C5/antagonistas & inibidores , Bibliotecas de Moléculas Pequenas/farmacologia , Complemento C5/metabolismo , Humanos , Conformação Molecular , Bibliotecas de Moléculas Pequenas/química
2.
SLAS Discov ; 26(8): 974-983, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-34151629

RESUMO

Affinity selection mass spectrometry (ASMS) has emerged as a powerful high-throughput screening tool used in drug discovery to identify novel ligands against therapeutic targets. This report describes the first high-throughput screen using a novel self-assembled monolayer desorption ionization (SAMDI)-ASMS methodology to reveal ligands for the human rhinovirus 3C (HRV3C) protease. The approach combines self-assembled monolayers of alkanethiolates on gold with matrix-assisted laser desorption ionization time-of-flight (MALDI TOF) mass spectrometry (MS), a technique termed SAMDI-ASMS. The primary screen of more than 100,000 compounds in pools of 8 compounds per well was completed in less than 8 h, and informs on the binding potential and selectivity of each compound. Initial hits were confirmed in follow-up SAMDI-ASMS experiments in single-concentration and dose-response curves. The ligands identified by SAMDI-ASMS were further validated using differential scanning fluorimetry (DSF) and in functional protease assays against HRV3C and the related SARS-CoV-2 3CLpro enzyme. SAMDI-ASMS offers key benefits for drug discovery over traditional ASMS approaches, including the high-throughput workflow and readout, minimizing compound misbehavior by using smaller compound pools, and up to a 50-fold reduction in reagent consumption. The flexibility of this novel technology opens avenues for high-throughput ASMS assays of any target, thereby accelerating drug discovery for diverse diseases.


Assuntos
Tratamento Farmacológico da COVID-19 , Ensaios de Triagem em Larga Escala , Rhinovirus/efeitos dos fármacos , Bibliotecas de Moléculas Pequenas/química , Proteases Virais 3C/química , COVID-19/virologia , Descoberta de Drogas , Humanos , Ligantes , Espectrometria de Massas , SARS-CoV-2/efeitos dos fármacos , SARS-CoV-2/patogenicidade , Bibliotecas de Moléculas Pequenas/isolamento & purificação , Bibliotecas de Moléculas Pequenas/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA